IPSC

Century Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Carr DouglasSVP Finance & Operations
$528289 shares
SellAug 5, 2024
$1.83
--
Quimi DaphneDirector
$7.7k5k shares
BuySep 12, 2024
$1.53
--
Carr DouglasSVP Finance & Operations
$347283 shares
SellNov 4, 2024
$1.23
--
Farid AdrienneChief Operations Officer
$1.3k1k shares
SellNov 4, 2024
$1.23
--
Carr DouglasSVP Finance & Operations
$274351 shares
SellFeb 3, 2025
$0.78
--
Farid AdrienneChief Operations Officer
$8221.1k shares
SellFeb 3, 2025
$0.78
--

News

globenewswire.comNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026globenewswire.comJun 8globenewswire.comNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026globenewswire.comJun 8globenewswire.comCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directorsglobenewswire.comMay 14globenewswire.comCentury Therapeutics Reports First Quarter Financial Results and Business Updatesglobenewswire.comMay 13globenewswire.comCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessionsglobenewswire.comApr 30